WHO ICTRP trial
A Phase 1 Study of MLN8237 in Japanese Patients with Relapsed and/or Refractory…
JPRN-jRCT2080221799 · Japan Primary Registries Network (JPRN)
Key facts
| Trial ID | JPRN-jRCT2080221799 |
|---|---|
| Public title | A Phase 1 Study of MLN8237 in Japanese Patients with Relapsed and/or Refractory Non-Hodgkin's lymphoma |
| Scientific title | A Phase 1 Study of MLN8237 in Japanese Patients with Relapsed and/or Refractory Non-Hodgkin's lymphoma |
| Primary sponsor | Takeda Pharmaceutical Company Limited |
| Registry | Japan Primary Registries Network (JPRN) |
| Study type | Interventional |
| Phase | 1 |
| Conditions | Non-Hodgkin's Lymphoma |
| Interventions | investigational material(s) Generic name etc : MLN8237 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Oral |
| Registration date | May 25, 2012 |
| Target size | 24 |
| Secondary IDs | JapicCTI-121841 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: